Immune checkpoint inhibitor induced large vessel vasculitis.

Authors :: Henderson D
Eslamian G
Poon D
Crabb S
Jones R
Sankey P
Kularatne B
Linch M
Josephs D
Source :: BMJ case reports [BMJ Case Rep] 2020 May 18; Vol. 13 (5). Date of Electronic Publication: 2020 May 18.
Publication Year :: 2020
Abstract: This is a case report of a 67-year-old patient with castration resistant metastatic prostate cancer who developed an immune-mediated large vessel vasculitis following treatment with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1).<br />Competing Interests: Competing interests: None declared.<br /> (© BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.)